t 457 rupees.Daiichi Sankyo, which owns 63.5 percent of Ranbaxy, paid 737 rupees a share in 2008.Ranbaxy would give Sun control over the competitor???s pipeline of generic products and help it expand in markets including Russia and Brazil.The company also needs to resolve production problems that led the Food and Drug Administration to ban four Ranbaxy plants from exporting to the U.S.The deal wil